Donate Help Contact The AHA Sign In Home
American Heart Association
Arteriosclerosis, Thrombosis, and Vascular Biology
Search: search_blue_button Advanced Search
Published Online
on January 15, 2009

Arteriosclerosis, Thrombosis, and Vascular Biology. 2009
Published online before print January 15, 2009, doi: 10.1161/ATVBAHA.108.182725
A more recent version of this article appeared on April 1, 2009
This Article
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow All Versions of this Article:
29/4/562    most recent
ATVBAHA.108.182725v1
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Das, A.
Right arrow Articles by Shah, V. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Das, A.
Right arrow Articles by Shah, V. H.
Right arrowPubmed/NCBI databases
*Gene*GEO Profiles
*HomoloGene*UniGene
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*L-TYROSINE

Submitted on August 8, 2008
Accepted on January 6, 2009

FXR Promotes Endothelial Cell Motility Through Coordinated Regulation of FAK and MMP-9

Amitava Das *; Usman Yaqoob ; Dolly Mehta ; and Vijay H. Shah

From the Gastroenterology Research Unit and Fiterman Center for Digestive Diseases (A.D., U.Y., V.H.S.), the Department of Internal Medicine (A.D., V.H.S.), Physiology and Cancer Cell Biology Program (V.H.S.), Mayo Clinic, Rochester, Minn; and the Department of Pharmacology (D.M.), University of Illinois, Chicago.

* To whom correspondence should be addressed. E-mail: das.amitava{at}mayo.edu.

Objective—Farnesoid X Receptor (FXR) mediates important signaling functions of bile acids in diverse cell types including those residing in the vascular wall. Indeed, recent work has identified FXR as a potential regulator of vascular structure and function in part through transcriptional activation of MMP-9. However, the signal transduction pathways linking bile acids to changes in actin cytoskeleton that are responsible for bile acid–induced vascular cell migration remain unexplored.

Methods and Results—The FXR agonist and prototypical bile acid, chenodeoxycholic acid (CDCA), significantly increased endothelial cell (EC) motility, as analyzed by time lapse video microscopy, and tube formation, an in vitro correlate for angiogenesis. Increased cell motility was associated with prominent increases in focal adhesion (FA) plaques and was inhibited by FXR or MMP-9 siRNA, indicating a FXR–MMP-9–dependency of this signaling pathway. Mechanistically, incubation of cells with CDCA was associated with phosphorylation of a key FA protein, Focal Adhesion Kinase (FAK) at Y397 but not at Y576/577, or Y925. Studies using a site-specific phosphorylation mutant (phosphodeficient) of FAK revealed that FAK phosphorylation at tyrosine residue -397 was required for CDCA induced activation of the downstream FA assembly protein, paxillin. Lastly, siRNA-based silencing of FAK as well as phosphodeficient FAK mutant inhibited CDCA induced upregulation of MMP-9, cell motility, and vascular tube formation.

Conclusion—Thus, this study demonstrates a pivotal role for FAK in the process of FXR-induced and MMP-9–dependent EC motility and vascular tube formation.


Key words: bile acids • FXR • MMP-9 • FAK • angiogenesis